It has been estimated that only a fraction of known disease targets have been successfully met with therapeutic options. As our understanding of disease biology continues to outpace our ability to develop therapeutic agents, there is an urgent need to find new ways to unlock a greater portion of this "undruggable" target space. Oligonucleotide and peptide therapeutics have emerged as critical development platforms to meet this challenge, poised to produce highly specific, diverse and safe therapies while addressing a much wider range of targets than traditional small molecules or biologics.
CHI's Third Annual Oligonucleotide & Peptide Therapeutics (OPT) Boston will once again convene leading developers and technology providers to discuss advances in next-generation oligonucleotide and peptide therapies. This three-day event includes two main conferences covering topics within discovery, delivery, and early clinical studies, as well as a symposium focused on utilizing oligonucleotides and peptides to address rare diseases.
200+ Participants • 84% from Leading Biotech & Pharma Companies • 43% growth in 2017
"No events go without a hitch, but your crack team met all the obstacle[s] head on, to our complete satisfaction. We've already signed up for the next event."
- Rick N., President, Oligo Factory
"It was my first time attending the show, and I was very impressed with the variety of speakers and content."
- Chris M., Ph.D. , Director, Business Development, Bachem Americas, Inc.
"This three-day meeting combines frontier works from both academic and industry which truly illustrated the current status of oligonucleotides therapeutics."
- Patrick L., Ph.D., President & CEO, Sirnaomics, Inc.